Objective-Dimethylglycine is linked to lipid metabolism, and increased plasma levels may be associated with adverse prognosis in patients with coronary artery disease. We evaluated the relationship between plasma dimethylglycine and risk of incident acute myocardial infarction in a large prospective cohort of patients with stable angina pectoris, of whom approximately two thirds were participants in a B-vitamin intervention trial. Model discrimination and reclassification when adding plasma dimethylglycine to established risk factors were obtained. We also explored temporal changes and the test-retest reliability of plasma dimethylglycine. Approach and Results-Four thousand one hundred fifty patients (72% men; median age 62 years) were included. Plasma dimethylglycine was associated with several traditional coronary artery disease risk factors. During a median follow-up of 4.6 years, 343 (8.3%) patients experienced an acute myocardial infarction. The hazard ratio (95% confidence interval) for acute myocardial infarction was 1.95 (1.42-2.68; P<0.001) when comparing plasma dimethylglycine quartile 4 to 1 in a Cox regression model adjusted for age, sex, and fasting status. Adjusting for traditional coronary artery disease risk factors only slightly modified the estimates, which were particularly strong among nonsmokers and among patients with serum triglyceride or apolipoprotein B100 levels ≤median (P for interaction=0.004, 0.004, and 0.03, respectively). Plasma dimethylglycine improved discrimination and reclassification and had high test-retest reliability. Conclusions-Plasma dimethylglycine is independently related to incident acute myocardial infarction and enhances risk prediction in patients with stable angina pectoris. Our results motivate further studies on the relationship between 1-carbon metabolism and atherothrombosis. A potential interplay with lipid and energy metabolism merits particular attention. (Arterioscler Thromb Vasc
A n increased risk of ischemic heart disease has been observed in patients with elevated blood choline, 1 plasma total homocysteine (tHcy), 2 and betaine 3 levels, although homocysteine-lowering B-vitamin treatment did not reduce risk of future cardiovascular disease (CVD) events in secondary prevention trials. 4 The tertiary amine dimethylglycine (DMG) is produced from betaine during the remethylation of homocysteine to methionine, catalyzed by betaine-homocysteine methyltransferase (BHMT; enzyme commission 2.1.1.5), an enzyme mainly confined to the liver and kidney. 5 DMG is metabolized to sarcosine in the mitochondria, 6 providing 1-carbon units for the formation of 5,10-methylenetetrahydrofolate. 7 A smaller proportion of DMG is excreted unmetabolized in the urine. 6 Blood levels of DMG relate to BHMT activity, 8, 9 but the association between circulating DMG and intracellular BHMT activity is complex, and DMG provides negative feedback on BHMT at physiological concentrations. 8 Lipid-lowering therapy with fibrates is associated with elevated tHcy levels 10 and reduced DMG catabolism, 11 thus linking both homocysteine and DMG with peroxisome proliferator-activated receptor α activation. BHMT induction has been related to enhanced hepatic apolipoprotein B (apoB) transcription and very low-density lipoprotein excretion, 12 and betaine supplementation in humans has been associated with increased levels of lowdensity lipoprotein cholesterol in serum. 13 The G allele of the single nucleotide polymorphism BHMT 742 G>A (rs3733890) is related to both higher plasma DMG levels 14 and more extensive coronary artery disease (CAD) in the elderly. 15 Notably, in a recent, small study of patients with established CAD, plasma DMG was associated with increased risk of all-cause death, acute myocardial infarction (AMI), and hospitalization for heart failure. 3 This suggests that the flux through BHMT or other determinants of plasma DMG may be related to the development of atherosclerotic CAD.
We explored the associations between baseline characteristics and plasma DMG and investigated the relationship between plasma DMG and the risk of subsequent AMI in a large cohort of patients undergoing coronary angiography for stable angina pectoris. We also evaluated the improvement in model discrimination and reclassification of patients at risk when adding plasma DMG to a model containing traditional CAD risk factors. In addition, we studied temporal changes and the test-retest variability of plasma DMG. The findings were reported according to the STrengthening the Reporting of OBservational studies in EpidemiologyMolecular Epidemiology (STROBE-ME) statement.
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Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
Characteristics of the Study Population According to Quartiles of Plasma DMG
Baseline characteristics of the study population are given in Table 1 . The cohort consisted of 72.0% men, and the median (5th-95th percentile) age was 62 (44-78) years. Thirty-one percent of the participants were current smokers, 11.8% were diagnosed with diabetes mellitus, 46.7% had hypertension, and 40.3% had a history of previous myocardial infarction. Baseline revascularization with either percutaneous coronary intervention or coronary artery bypass grafting was performed in 2177 (52.4%) patients.
Median (5th-95th percentile) plasma DMG was 4. There was a positive linear relationship between incremental DMG quartiles and age and C-reactive protein, whereas a negative association was observed with estimated glomerular filtration rate (eGFR). Subjects in higher DMG quartiles more often were smokers, had hypertension and established CVD, whereas plasma DMG was not associated with left ventricular ejection fraction and was only borderline significantly related to the number of stenosed coronary arteries at angiography. As expected, DMG was strongly related to other 1-carbon metabolites (plasma choline, betaine, tHcy, methionine, and sarcosine), but except for a positive association with plasma methylmalonic acid, there was no relationship between DMG and various markers of B-vitamin status in age-and sex-adjusted analyses. We further observed an inverse trend between plasma DMG quartiles and total cholesterol, highdensity lipoprotein cholesterol, and apolipoprotein A1 levels, whereas there were minor or no associations with other lipid parameters. Patients with higher DMG more often used β-blockers and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. We did not observe any association between plasma DMG and plasma glucose, body mass index, or diabetes mellitus. When comparing fasting with nonfasting patients (Tables I  and II in the online-only Data Supplement), we observed similar associations with DMG for most variables (P for interaction ≥0.05), except for left ventricular ejection fraction and previous myocardial infarction (P for interaction=0.01 for both).
The minor A allele frequency of the BHMT 742 G>A polymorphism was 0.27, and the genotypes were in HardyWeinberg equilibrium 17 for all patients investigated, as well as for cases and controls separately (P≥0.06). Plasma DMG was inversely related to the minor allele, but we did not find any association between the polymorphism and the extent of CAD (P for trend=0.43) in age-and sex-adjusted analysis.
Predictors of Subsequent AMI
Median (5th-95th percentile) follow-up time was 4.6 (1.6-6.8) years, constituting a total of 18 848 patient-years. Three hundred forty-three (8.3%) patients experienced an AMI, of which 103 (30.0%) were fatal. The incidence rate for AMI was thus 1.8 events per 100 patient-years. Using Cox regression analyses we found an approximately linear trend between plasma DMG and subsequent AMI ( Table 2 and Figure 2 ). In an unadjusted Cox regression Continuous variables are reported as median (5th-95th percentiles), and categorical variables are reported as counts (%). ACEI indicates angiotensin-converting enzyme inhibitor; apoA1, apolipoprotein A1; apoB, apolipoprotein B; ARB, angiotensin receptor blocker; BHMT, betaine-homocysteine methyltransferase; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CBV, cerebrovascular disease; CRP, C-reactive protein; DMG, dimethylglycine; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MMA, methylmalonic acid; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PLP, pyridoxal phosphate; and tHcy, total homocysteine.
* As depicted in Figure 3 and .002], respectively), whereas there was no association between DMG and incident AMI among smokers or among those with serum TG or apoB100 levels above the median (P for interaction=0.004, 0.004, and 0.03, respectively). Accordingly, in patients with DMG levels above median, neither smoking nor high serum TG or apoB100 levels were statistically significantly associated with incident AMI (Table VII in the online-only Data Supplement). Because statin therapy influences circulating TG and apoB100 levels, we excluded subjects who either altered their statin doses or started statin therapy at baseline (654 patients, 42 AMI events) and obtained similar results (data not shown). There were borderline statistically significant stronger associations between plasma DMG and AMI in patients with eGFR ≤median (P for interaction=0.06) and age >median (P for interaction=0.07). We did not find any effect modification by any of the other subgroup parameters (P for interaction ≥0.16; Table VI in the online-only Data Supplement).
When further exploring these subgroups according to fasting status, we found some variations in the relationship between plasma DMG and incident AMI (Table VIII in the online-only Data Supplement). Notably, in patients with fasting TG levels ≤median, we observed a >7-fold increased risk of AMI in the upper versus the lower DMG quartile. A particularly high risk of incident AMI was also noticed in fasting patients with serum apoB100 ≤median. However, fasting status did not add any statistically significant effect modification to any of the subgroups or when examining the total population (P for interaction ≥0.05). We found no association between the BHMT 742 G>A polymorphism and the risk of incident AMI in case-control analyses (Tables IX and X in 
Discrimination and Reclassification of AMI by Plasma DMG
When added to the Cox regression model 2, plasma DMG increased the C statistic (95% CI) by 0.012 (0.001-0.022).
Even larger increments were observed in subgroups of nonsmokers and those with serum TG and apoB100 ≤median, although the latter was only borderline statistically significant ( Table 3 ). 
Changes in Plasma DMG Over Time and Test-Retest Reliability
Mean (SEM) plasma DMG levels rose from 4.29 (0.03) µmol/L at baseline to 4.45 (0.03) µmol/L at the end of study in the 2565 patients enrolled in Western Norway B-vitamin Intervention Trial (WENBIT; P<0.001). The median (5th-95th percentile) follow-up time was 3.3 (1.8-5.0) years. However, a temporal increase in DMG levels from baseline to the end of study was only seen in patients randomized to receive vitamin B6 (P<0.001), whereas a borderline statistically significant increase was observed in those allocated to receive placebo (P=0.07). There were no time-dependent changes in plasma DMG among patients treated with folic acid, vitamin B12, and vitamin B6 (P=0.94) or in those allocated to receive folic acid and vitamin B12 (P=0.22). No interaction with fasting status was observed (P≥0.08). The coefficients of reliability for plasma DMG and log-transformed plasma DMG throughout these repeated measurements were 0.93 and 0.73, respectively.
Discussion
This large, prospective cohort study of patients undergoing elective coronary angiography for stable angina pectoris showed that patients with elevated plasma DMG levels were more likely to experience an AMI, even after extensive adjustment for traditional cardiovascular risk factors. The association was stronger than for most other metabolites related to the choline oxidation pathway and was most pronounced in nonsmokers and in subjects with low serum apoB100 or TG levels, in whom a particularly strong relationship was suggested among the minority with fasting blood samples at baseline. Plasma DMG also significantly improved discrimination and reclassification of patients at risk and showed high test-retest reliability over >3 years. 
DMG and CAD
Data on the relationship between DMG and CAD are scarce. Most importantly, our results extend the findings from an investigation of 531 patients with recent acute coronary syndrome, reporting a positive relationship between plasma DMG at baseline and the risk of incident AMI during ≈2.5 years of follow-up. 3 Increased urinary DMG levels have been observed in patients with premature vascular disease, 18 and serum levels of sarcosine, the immediate catabolic product of DMG, has been associated with restenosis after percutaneous coronary intervention.
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DMG and Other Baseline Characteristics
In the present investigation, DMG levels were higher among patients with established CVD, and we observed a borderline significant relationship between DMG and the extent of CAD, as evaluated by coronary angiography. In line with findings in the general population, 14 we found the BHMT 742 G>A G allele to be associated with higher plasma DMG levels. This allele has been related to more extensive CAD in elderly subjects. 15 However, in agreement with a recent meta-analysis, 20 we did not observe any overall association between the BHMT 742 G>A genotype and extent of CAD in the present study. As in previous reports 3, 14, 21 plasma DMG levels in the current study were higher in men than in women. DMG was also higher among patients with established CAD risk factors, such as older age, hypertension, and smoking. We found a strong inverse association between plasma DMG levels and eGFR, in agreement with earlier studies among patients with renal failure. 8, 22 B vitamins are important as cofactors in 1-carbon metabolism, and folate deficiency has been related to increased BHMT flux. 21 DMG tended to be weakly, inversely related to serum folate at baseline in nonfasting subjects, and folic acid supplementation (in WENBIT) seemed to prevent a time-dependent 4% to 10% increase in plasma DMG during follow-up. There was a positive association between baseline plasma DMG and methylmalonic acid, although no relationship was observed between DMG and cobalamin levels.
Possible Mechanisms
Experimental studies have demonstrated that dietary betaine increases the expression of both BHMT and apoB, suggesting a link at the level of gene transcription. 12 We found no or only weak, negative associations between plasma DMG quartiles and serum total cholesterol, TG, low-density lipoprotein cholesterol, and apoB100; however, putative associations may be masked by statin therapy. The relationship between DMG and AMI was most pronounced among patients with low TG or apoB100 levels, and there was a tendency toward an even stronger association among patients in the fasting state. Others have demonstrated that TG lowering by the peroxisome proliferatoractivated receptor α agonist WY14 643 reduces transcription of the enzymes involved in DMG and sarcosine catabolism. 11 Of note, peroxisome proliferator-activated receptor α influences the handling of energy substrates derived from lipids, 23 amino acids, 24 and carbohydrates. 25 Hence, high plasma DMG levels may be related to the regulation of lipid and energy metabolism.
The effect modification by smoking is not readily explained; however, the current and previous studies have shown that levels of various 1-carbon metabolites are associated with smoking. [26] [27] [28] Furthermore, the observation that plasma DMG did not predict risk of AMI in several groups of patients with a high burden of other risk factors may suggest common mechanistic pathways or masking of the DMG-AMI association in such patients.
Adding eGFR to the Cox regression model 2 somewhat attenuated the association between plasma DMG levels and future AMI, and we found a borderline statistically significant effect modification by eGFR. Declined renal function is considered a major CAD risk factor 29 ; hence, our findings indicate that the enhanced risk of AMI by high plasma DMG levels could partly be mediated through similar mechanisms as in subjects with renal impairment.
An increased risk of ischemic heart disease has been associated with elevated blood levels of choline, 1 betaine, 3 and tHcy. 2 Choline is the precursor of betaine and thus interrelated with homocysteine in the production of DMG. Notably, 2 recent studies have proposed a plausible mechanism as to how dietary choline and phosphatidylcholine may promote atherosclerosis 30 and augment the risk of cardiovascular events and mortality via gut microbial-dependent formation of trimethylamine N-oxide. 31 We did not assess dietary data in the current study nor did we measure circulating trimethylamine N-oxide levels. However, prospective studies in the general population have not found statistically significant associations between choline and betaine intake and the risk of CVD.
1 Accordingly, in our study, no relationship between either plasma choline or betaine levels and the risk of AMI was observed in multivariate analyses, also including DMG. Furthermore, the association of AMI risk with plasma DMG was only slightly attenuated by adjustment for tHcy, making homocysteine an unlikely confounder. Thus, our findings extend the current knowledge of the association between 1-carbon metabolites and CVD.
High plasma DMG levels may reflect altered flux through BHMT, influencing liver S-adenosylmethionine levels 32 and thereby the availability of methyl groups for transmethylation reactions, including synthesis of phosphatidylcholine, the major phospholipid in very low-density lipoprotein particles. Thus, increased DMG may be linked to changes in lipoprotein assembly. However, the BHMT 742 G>A polymorphism was not associated with the extent of CAD nor was it related to the risk of incident AMI, despite plasma DMG levels being inversely associated with the minor allele. Importantly, if the A allele were to provide protection from suffering an AMI, the issue of statistical power must be considered. The various genetic models would require a maximum event rate of ≈4% in groups with the minor allele, compared with the 8.3% event rate in the total population, using α-and β-levels set to 0.05 and 0.80, respectively. Furthermore, as CAD is considered being of multifactorial etiology, an ≈50% reduction in event rate is not likely caused by 1 single genetic determinant. 33 The BHMT pathway is the only source of DMG. Thus, large Mendelian randomization studies 34 of BHMT genotypes could shed more light on whether DMG is causally related to AMI risk. However, genes are often multifunctional, hence their pleiotropic effects are part of the inherent weaknesses of such studies.
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Strengths and Limitations
The major strengths of this study are its prospective design and large study sample and detailed clinical characterization of the population. Furthermore, we have recently shown that plasma DMG is stable during both short-and long-term storage 36 and now report a high test-retest reliability of plasma DMG, which allow 1-exposure assessment of DMG status. We cannot rule out underreporting or misclassification of clinical end points, which would weaken rather than strengthen the observed associations.
Furthermore, residual confounding might influence the assessment of risk predictors in observational cohort studies, which do not allow inference on causality or on flux through metabolic pathways. We mainly studied white, elderly men with stable coronary heart disease, and our results may not apply to women and subjects in other age and ethnic groups or to subjects with clinical features other than stable angina pectoris.
Conclusion
In conclusion, we found that plasma DMG levels are strongly and independently associated with risk of future AMI in patients with stable angina pectoris and adds improvement in risk prediction and discrimination, particularly in subgroups at presumably lower risk. The current findings motivate further studies to elucidate possible mechanisms of 1-carbon metabolism in atherothrombosis. Such research should also consider the potential interaction with energy and lipid metabolism.
